Trial Profile
Phase II Trial of Ibrutinib in Perviously Untreated High Risk Smoldering Mantle Cell Lymphoma (MCL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Results assessing safety and efficacy of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 16 Oct 2023 Planned End Date changed from 28 Feb 2025 to 28 Feb 2026.
- 16 Oct 2023 Planned primary completion date changed from 28 Feb 2024 to 28 Feb 2026.